International Stem Cell Corp. to launch joint supplement for osteoarthritis pain in Q3 2018

Shayna Korol -   Print  |

International Stem Cell Corporation plans to launch its advanced joint supplement for the treatment of osteoarthritis-related joint pain in the third quarter of 2018.

The company focuses on developing human parthenogenetic stem cells for therapeutic applications. This initial launch will focus on the company's existing Lifeline Skin Care customers. 

According to the CDC, osteoarthritis is the most common form of degenerative joint disease and affects approximately 630 million people around the globe. Technavio analysts predict that the global bone and joint supplements market will reach $3.3 billion by the end of 2023.

More articles on biologics:

How Dr. Kevin Stone helped Super Bowl champion Tracy Porter make a comeback — 6 details

Study: First-in-human neural stem cell transplantation shows promise for spinal cord injury treatment — 5 takeaways

How PolarityTE aims to bring 'an entirely new treatment paradigm' to orthopedics & spine — 7 Qs with Dr. Ned Swanson

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers